Drug Target and Biomarker: CREB1 (G1385)

Target Name: CREB1

NCBI ID: G1385

CREB1

Other Name(s): Cyclic AMP-responsive element-binding protein 1 | CAMP responsive element binding protein 1, transcript variant 1 | CAMP responsive element binding protein 1, transcript variant 2 | CREB1_HUMAN | CREB

Drug Target and Biomarker: CREB1

T. cruzi infection of colonic epithelial cells leads to the phosphorylation of CREB, which is translocated into the nuclei of infected cells, potentially contributing to the pathology observed in chagasic individuals.
CREB plays a role in promoting the generation and maintenance of regulatory T cells (Tregs) through its phosphorylation and binding to the FoxP3 locus, which regulates FoxP3 expression.
Phosphorylation of CREB, through recruitment of p300/CBP, contributes to the regulation of hepatic glucose homeostasis by influencing the expression of genes involved in gluconeogenesis.
CREB1 is involved in HDAC3-regulated breast cancer progression, where HDAC3 transactivates KDELR2 via CREB1, leading to accelerated cell cycle progression and tumor growth.
Certain herbal components, such as Rehmannia Root, Moutan Bark, and Cornus Fruit, inhibit the transactivation of CREB induced by glucagon, potentially affecting the expression of genes involved in glucose metabolism.

Please note that the viewpoints have been extracted and summarized based on the provided context, and no prior knowledge has been used. References have been cited using the corresponding numbers.
Based on the given context information and the keyword "CREB," we can extract the following key viewpoints:

Astrocyte marker GFAP has the highest correlation with prefrontal cortex aging and is causally dependent on CAMK4. The time series of GFAP and CAMK4 show a positive and negative correlation with age, respectively.

CAMK4 regulates GFAP, possibly through pERK and CREB signaling pathways. Down-regulation of GFAP during aging is marked with a green color, while up-regulation is marked with red.

Activation of astrocytes (marked by GFAP) is triggered by inflammation, reactive oxygen species (ROS), and neuronal injury. Astrocytes regulate the uptake and release of neurotransmitters responsible for synaptic transmission.

GFAP is involved in the regulation of inflammatory processes in response to neuronal injury and ROS. This suggests that GFAP plays a role in the brain's response to damage and inflammation.

Calcium signaling pathway is downstream of CREB and may be involved in the regulation of GFAP. The downregulation of CAMK4 during aging may contribute to the decline of GFAP expression.

In summary, GFAP, a marker of astrocytes, shows a strong correlation with aging in the prefrontal cortex and is dependent on CAMK4. Both astrocytes and GFAP are involved in regulating inflammatory processes in response to neuronal injury and ROS. GFAP is regulated by CAMK4, possibly through the pERK and CREB signaling pathways, and is influenced by the calcium signaling pathway.

Protein Name: CAMP Responsive Element Binding Protein 1

Functions: Phosphorylation-dependent transcription factor that stimulates transcription upon binding to the DNA cAMP response element (CRE), a sequence present in many viral and cellular promoters. Transcription activation is enhanced by the TORC coactivators which act independently of Ser-119 phosphorylation. Involved in different cellular processes including the synchronization of circadian rhythmicity and the differentiation of adipose cells

The "CREB1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CREB1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets